tiprankstipranks
Trending News
More News >

Vivos Therapeutics downgraded to Neutral from Buy at Alliance Global Partners

Alliance Global Partners analyst Scott Henry downgraded Vivos Therapeutics (VVOS) to Neutral from Buy with a price target of $2.25, down from $5.50. The firm views the company’s visibility as low pending signs of execution for its new business model, which it says is unlikely before the second half of 2025. Vivos has limited financial resources to manage this uncertainty, the analyst tells investors in a research note. Alliance points out the company’s Q1 results trailed forecasts as the business model shifts from dentists to sleep specialists.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue